Interindividual variability in 2-hydroxylation, 3-sulfation, and 3-glucuronidation of ethynylestradiol in human liver
- PMID: 15577203
- DOI: 10.1248/bpb.27.1900
Interindividual variability in 2-hydroxylation, 3-sulfation, and 3-glucuronidation of ethynylestradiol in human liver
Abstract
In the current study, we investigated interindividual variability of the 2-hydroxylation, 3-glucuronidation, and 3-sulfation of ethynylestradiol (EE2) using human liver microsomes and cytosol. Km values for the 2-hydroxylation and 3-glucuronidation in pooled liver microsomes and for the 3-sulfation in pooled liver cytosol were 3.34, 23.3, and 2.85 microM, respectively. Vmax/Km (ml/min/g liver) was highest for the 3-sulfation, followed by 2-hydroxylation, suggesting that 3-sulfation is the major metabolic pathway of EE2 in human liver. All further studies were performed at a substrate concentration of 0.1 microM. Microsomal 2-hydroxylation and 3-glucuronidation activities ranged from 0.21 to 5.02 (2.04+/-1.34, mean+/-S.D., n=35) and 0.20 to 4.84 (1.20+/-1.00, n=35) pmol/min/mg protein, respectively. Cytosolic 3-sulfation activity ranged from 4.2 to 24.3 (11.8+/-4.4, n=21) pmol/min/mg protein. All the measured enzyme activities were neither gender-related nor age-dependent, except that 2-hydroxylation was significantly higher in females than in males (p<0.05). The relative contribution of CYP3A to the 2-hydroxylation in liver microsomes was estimated from the degree of inhibition by 1 microM ketoconazole. The degrees of inhibition were between 17.8 and 78.0% (51.6+/-16.0%, n=27). These results indicate that there are large interindividual differences in the enzyme activities towards the respective metabolic pathways of EE2 and the relative contribution of CYP3A to the 2-hydroxylation of EE2 in human liver.
Similar articles
-
Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver.Br J Clin Pharmacol. 1991 Jun;31(6):661-4. doi: 10.1111/j.1365-2125.1991.tb05589.x. Br J Clin Pharmacol. 1991. PMID: 1907838 Free PMC article.
-
Study on effects of p-phenylbenzoic acid on change of sulfation and glucuronidation in rats.Biol Pharm Bull. 2002 May;25(5):686-9. doi: 10.1248/bpb.25.686. Biol Pharm Bull. 2002. PMID: 12033518
-
Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol.Biol Pharm Bull. 2004 Nov;27(11):1844-9. doi: 10.1248/bpb.27.1844. Biol Pharm Bull. 2004. PMID: 15516735
-
Metabolism of 17 alpha-ethynylestradiol in humans.Life Sci. 1990;47(22):1981-8. doi: 10.1016/0024-3205(90)90431-p. Life Sci. 1990. PMID: 2273938 Review.
-
Interindividual variation in the metabolism of ethynylestradiol.Pharmacol Ther. 1989;43(2):251-60. doi: 10.1016/0163-7258(89)90121-6. Pharmacol Ther. 1989. PMID: 2675136 Review. No abstract available.
Cited by
-
Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27. Clin Pharmacol Ther. 2018. PMID: 29637542 Free PMC article.
-
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.Clin Pharmacokinet. 2007;46(2):133-57. doi: 10.2165/00003088-200746020-00003. Clin Pharmacokinet. 2007. PMID: 17253885 Review.
-
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.Eur J Clin Pharmacol. 2019 Jan;75(1):41-49. doi: 10.1007/s00228-018-2549-7. Epub 2018 Sep 6. Eur J Clin Pharmacol. 2019. PMID: 30191262 Clinical Trial.
